Page 2 - நடாலி மாலை கோலின்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நடாலி மாலை கோலின்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நடாலி மாலை கோலின்ஸ் Today - Breaking & Trending Today

Investegate |Syncona Limited Announcements | Syncona Limited: Achilles reports Q1 financial results

- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

London, UK 11 May 2021
- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.

Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating our precision TIL cNeT therapy in patients with non-small cell lung cancer and melanoma, respectively, and priced our successful US initial public offering on Nasdaq, which closed just after quarter-end, said Dr Iraj Ali, Chief Executive Officer of Achilles. We continue to enroll an ....

United States , United Kingdom , City Of , Melissa Gardiner , Collins Tim Stamper , Sukaina Virji , Markwin Velders , Julie Oneill , Miraj Ali , Mary Jane Elliott , Annabel Clay , Ben Atwell Natalie , Centre Phasei Iia , Data Safety Monitoring Committee , American Association Of Cancer Research , Research Development , Ir External Communications , Neoantigen Consortium , Achilles Therapeutics Plc , Syncona Ltd , Consilium Strategic Communications , Syncona Limited , First Quarter , Natalie Garland Collins , Therapeutics Reports First Quarter , Recent Business ,

Investegate |Syncona Limited Announcements | Syncona Limited: Gyroscope Therapeutics update on proposed IPO

Tel: +44 (0) 20 3727 1000

About Syncona
Syncona s purpose is to invest to extend and enhance human life. We do this by founding, building and funding a portfolio of global leaders in life science, to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our strategic balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders. ....

New York , United States , United Kingdom , City Of , San Francisco , Charlotte Arnold , Collins Tim Stamper , Khurem Farooq , Annabel Clay , Ben Atwell Natalie , Broadridge Financial Solutions , Syncona Ltd Is Andrew Cossar , Drug Administration , Gyroscope Therapeutics Holdings , Financial Services , Exchange Commission , Prospectus Department , European Union , Goldman Sachs Co , Syncona Ltd , Citigroup Global Markets Inc , Morgan Stanley Co , Corporate Affairs , Market Abuse Regulation , Andrew Cossar , General Counsel ,

Investegate |Syncona Limited Announcements | Syncona Limited: Autolus reports Q1 2021 Financial Results

06 May 2021
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ: AUTL) (Autolus), announced its operational and financial results for the first quarter ended March 31, 2021.
The announcement can be accessed on Autolus investor website at
https://www.autolus.com/investor-relations
and full text of the announcement from Autolus is contained below. Autolus management will host a conference call today, at 8:30 a.m. EDT/ 1:30pm GMT to discuss the company s financial results and operational update. To listen to the webcast and view the accompanying slide presentation, please go to: ....

City Of , United Kingdom , United States , Susana Noonan , Julia Wilson , Collins Tim Stamper , Martin Murphy , Annabel Clay , Muhammad Al , Ben Atwell Natalie , Exchange Commission On , European Hematology Association , Sa Noonan Communications , International Nonproprietary Name , Translational Sciences , Regulatory Agency , Exchange Commission , Autolus Therapeutics Plc , European Medicines Agency , Syncona Ltd , Syncona Limited , Natalie Garland Collins , Therapeutics Reports First Quarter , Autolus Therapeutics , Christian Itin , Acute Lymphoblastic Leukemia ,

Newron Pharmaceuticals S.p.A.: Newron Announces Paragraph IV ANDA Filing for Xadago (safinamide) in the USA

Newron Pharmaceuticals S.p.A.: Newron Announces Paragraph IV ANDA Filing for Xadago (safinamide) in the USA
Newron Pharmaceuticals S.p.A. ( Newron ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it received a Paragraph IV Notice Letter regarding the submission by a generic manufacturer of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA), seeking approval to engage in the commercial manufacture, use or sale of safinamide mesylate drug product in the U.S. before expiration of certain US patents. ....

Kyongsang Bukto , South Korea , United States , United Kingdom , United Arab Emirates , Anne Hennecke Caroline Bergmann , Paul Sagan , Simon Conway Natalie , Stefan Weber , Valentin Handschin , Mc Services , European Union , Newron Pharmaceuticals , Drug Administration , Supernus Pharmaceuticals , Swiss Exchange , Abbreviated New Drug Application , Notice Letter , Drugs Product List , Orange Book , Meiji Seika , Natalie Garland Collins , Caroline Bergmann , தெற்கு கொரியா , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் ,

Investegate |Syncona Limited Announcements | Syncona Limited: Autolus appoints non-executive Chair

Investegate |Syncona Limited Announcements | Syncona Limited: Autolus appoints non-executive Chair
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , City Of , Susana Noonan , Julia Wilson , Collins Tim Stamper , Martin Murphy , Annabel Clay , Ben Atwell Natalie , Exchange Commission On , Syncona Investment Management , Sa Noonan Communications , Syncona Investment Management Limited , Exchange Commission , Autolus Therapeutics Plc , Syncona Ltd , Chief Executive Officer , Syncona Limited , Natalie Garland Collins , Non Executive Chairman , Autolus Therapeutics , Christian Itin , Autolus Board , Private Securities Litigation Reform Act , Autolu Annual Report , ஒன்றுபட்டது மாநிலங்களில் ,